Immunophage Biotech, a Nanjing-based pharmaceutic company, has recently completed a Pre-A round of financing of nearly RMB100 million (US$14.2 million), led by Jinfang Hongrui Investment Management, according to Chinese media report. Nanjing Enran Ruiguang Health Industry Investment Partnership, Zibo Jinfang Hengjian Equity Investment Fund Partnership, Qingdao Zhongtai Huiyin Investment Management Partnership, Nanjing Yangzi Technology Venture […]

Immunophage Biotech Gets $14M In Pre-A Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.